Breast cancer subtypes originate from different biological pathways

Key points
- There is a biological distinction between breast cancers that depend on hormones and those that do not, according to research published Friday, April 25th in the open-access journal PLoS Genetics.
- This press release refers to an upcoming article in PLoS Genetics.
- Scientists previously thought that hormone dependent breast cancers, which usually require treatment with surgery and anti-hormone drugs, originated from the same biological pathway as hormone independent breast cancers, which are treated with surgery and chemotherapy.
- Paul Pharoah, lead author based at the University of Cambridge, said: “We looked at five genetic variants associated with breast cancer to see if they were more likely to be found in hormone dependent or independent breast cancers.
There is a biological distinction between breast cancers that depend on hormones and those that do not, according to research published Friday, April 25th in the open-access journal PLoS Genetics.
Scientists previously thought that hormone dependent breast cancers, which usually require treatment with surgery and anti-hormone drugs, originated from the same biological pathway as hormone independent breast cancers, which are treated with surgery and chemotherapy.
In the largest study of its kind, an international consortium of cancer researchers studied the genetic makeup of over 23,000 breast cancer cases.*
Dr. Paul Pharoah, lead author based at the University of Cambridge, said: “We looked at five genetic variants associated with breast cancer to see if they were more likely to be found in hormone dependent or independent breast cancers. One common genetic variant, FGFR2, was strongly associated with hormone dependent breast cancer, but weakly associated with hormone independent cancer. This shows that they have distinct genetic origins, and are different diseases.”
Dr Lesley Walker, Cancer Research UK’s director of cancer information, said: “Scientists were previously unsure how different types of breast cancer developed. Although the findings won’t have any immediate effects on the treatment of women with the disease, they are important in helping to define the next steps in our research on the causes of this major cancer.”
This discovery provides strong evidence that the subtypes originate from separate pathways and could guide future research into prevention and treatments for the cancer types as different diseases. This study was funded by Cancer Research UK.
###
Note to Editors:
* The researchers in this study used data provided by the Breast Cancer Association Consortium (BCAC) – a huge international collaborative group of researchers interested in inherited risk of breast cancer. Co-ordination of BCAC is funded by Cancer Research UK.
Hormone dependent breast cancers are also known as ER positive and hormone independent breast cancers as ER negative.
PLEASE ADD THIS LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://www. plosgenetics.org/doi/pgen.1000054 (link will go live on Friday, April 25)
CITATION: Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, et al. (2008) Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. PLoS Genet 4(4): e1000054. doi:10.1371/journal.pgen.1000054
CONTACT:
Rachel Gonzaga
Science Press Officer
Cancer Research UK
Office: 020 7061 8252
Out-of-Office Hours Duty Press Officer: 07050 264 059
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNeoadjuvant use of pertuzumab in HER2-positive breast cancer
Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable…
4 December 2015
NewsPotential new therapy for triple-negative breast cancer shows promise in lab studies
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease. In a recent study…
28 October 2015
NewsUGR scientists patent an effective drug for treating breast, colon, and skin cancers
Scientists from the University of Granada (UGR) have patented an effective drug for treating cancer stem cells (CSCs) in breast, colon, and skin cancers. The researchers have proved the anti-tumor effects of the drug on…
21 October 2015


